$BCRX Cashflow Statement | Understand Stock

$BCRX

$8.09 +$0.21 (2.66%) Live

$BCRX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization
Inventory obsolescence
Stock-based compensation expense
Amortization of premium/discount on investments
Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs
Equity modification associated with sale of BioCryst Ireland
Mark-to-market adjustment on share-based liability
Payment of Pharmakon PIK Interest
Non-cash interest expense on royalty financing obligations
Non-cash interest expense on secured term loan and amortization of debt issuance costs
Amortization of discount on investments, net
Change in fair value of foreign currency derivative
Loss on extinguishment of debt
Loss on impairment
Gain on sale of non-financial asset
Gain on sale of BioCryst Ireland

Changes in operating assets and liabilities:
Increase in receivables
Increase in inventory
(Increase) decrease in prepaid expenses and other assets
Decrease in royalty financing obligations
Increase in accounts payable and accrued expenses
Interest payable
Decrease in deferred revenue
Net cash provided by (used in) operating activities
Cash flows from investing activities:
Acquisitions of property and equipment
Purchases of investments
Sales and maturities of investments
Sale of non-financial asset
Proceeds from sale of BioCryst Ireland, net of cash divested
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Payment of senior credit facility
Net proceeds from secured term loan
Net proceeds from common stock issued under stock-based compensation plans
Withholding taxes paid on stock-based awards
Common stock issued to directors in lieu of cash retainer
Net proceeds from term loans
Repayment of principal on term loans
Prepayment premium and fees on term loans
Payment of debt issuance costs on Pharmakon Tranche A term loan
Principal payments on royalty financing obligations
Payment of royalty release fees
Principal payments on finance lease liabilities
Net proceeds from royalty financing liabilities
Net cash (used in) provided by financing activities
Effects of exchange rates on cash, cash equivalents and restricted cash

Effect of exchange rates on cash, cash equivalents and restricted cash
Decrease in cash, cash equivalents and restricted cash
Beginning of year
End of year
Supplemental cash flow disclosure:
Cash paid for interest
Cash paid for taxes
Taxes withheld on stock-based awards included in accrued expenses
Capitalized software costs included in accrued expenses
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
Restricted cash
Restricted cash in other assets

Comments